Skip to main content

Advertisement

Log in

10 K: a large‐scale prospective longitudinal study in Israel

  • COHORT PROFILE
  • Published:
European Journal of Epidemiology Aims and scope Submit manuscript

Abstract

The 10 K is a large-scale prospective longitudinal cohort and biobank that was established in Israel. The primary aims of the study include development of prediction models for disease onset and progression and identification of novel molecular markers with a diagnostic, prognostic and therapeutic value. The recruitment was initiated in 2018 and is expected to complete in 2021. Between 28/01/2019 and 13/12/2020, 4,629 from the expected 10,000 participants were recruited (46 %). Follow-up visits are scheduled every year for a total of 25 years. The cohort includes individuals between the ages of 40 and 70 years. Predefined medical conditions were determined as exclusions. Information collected at baseline includes medical history, lifestyle and nutritional habits, vital signs, anthropometrics, blood tests results, Electrocardiography, Ankle–brachial pressure index (ABI), liver US and Dual-energy X-ray absorptiometry (DXA) tests. Molecular profiling includes transcriptome, proteome, gut and oral microbiome, metabolome and immune system profiling. Continuous measurements include glucose levels using a continuous glucose monitoring device for 2 weeks and sleep monitoring by a home sleep apnea test device for 3 nights. Blood and stool samples are collected and stored at − 80 °C in a storage facility for future research. Linkage is being established with national disease registries.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

Data Availability

Access to the 10 K cohort is currently not available online. Potential collaborators are encouraged to contact the Principal Investigator by e-mail (eran.segal@weizmann.ac.il) for further information.

References

  1. Diabetes Prevention Program Research Group. Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677–86.

    Article  Google Scholar 

  2. Knoops KTB, de Groot LCPGM, Kromhout D, Perrin A-E, Moreiras-Varela O, Menotti A, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA. 2004;292:1433–9.

    Article  Google Scholar 

  3. Shilo S, Rossman H, Segal E. Axes of a revolution: challenges and promises of big data in healthcare. Nat Med. 2020;26:29–38.

    Article  CAS  Google Scholar 

  4. Kinkorová J. Biobanks in the era of personalized medicine: objectives, challenges, and innovation: Overview. EPMA J. 2015;7:4.

    Article  Google Scholar 

  5. Rothschild D, Weissbrod O, Barkan E, Kurilshikov A, Korem T, Zeevi D, et al. Environment dominates over host genetics in shaping human gut microbiota. Nature. 2018;555:210–5.

    Article  CAS  Google Scholar 

  6. UK Biobank: Protocol for a large-scale prospective epidemiological resource avilable at https://www.ukbiobank.ac.uk/learn-more-about-ukbiobank/about-us (accessed 23 July, 2020).

  7. Blaser MJ. Antibiotic use and its consequences for the normal microbiome. Science. 2016;352:544–5.

    Article  CAS  Google Scholar 

  8. Halfvarson J, Brislawn CJ, Lamendella R, Vázquez-Baeza Y, Walters WA, Bramer LM, et al. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat Microbiol. 2017;2:17004.

    Article  CAS  Google Scholar 

  9. Pang KP, Gourin CG, Terris DJ. A comparison of polysomnography and the WatchPAT in the diagnosis of obstructive sleep apnea. Otolaryngol Head Neck Surg. 2007;137:665–8.

    Article  Google Scholar 

  10. Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut microbiota on human health: an integrative view. Cell. 2012;148:1258–70.

    Article  CAS  Google Scholar 

  11. Lawlor DA, Harbord RM, Sterne JAC, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27:1133–63.

    Article  Google Scholar 

  12. Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183:758–64.

    Article  Google Scholar 

  13. Hernán MA, Robins JM. Estimating causal effects from epidemiological data. J Epidemiol Commun Health. 2006;60:578–86.

    Article  Google Scholar 

  14. Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47:856–60.

    Article  CAS  Google Scholar 

  15. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. Am J Epidemiol. 2017;186:1026–34.

    Article  Google Scholar 

  16. Swanson JM. The UK Biobank and selection bias. Lancet. 2012;380:110.

    Article  Google Scholar 

  17. Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, et al. Personalized nutrition by prediction of glycemic responses. Cell. 2015;163:1079–94.

    Article  CAS  Google Scholar 

  18. Zeevi D, Korem T, Godneva A, Bar N, Kurilshikov A, Lotan-Pompan M, et al. Structural variation in the gut microbiome associates with host health. Nature. 2019;568:43–8.

    Article  CAS  Google Scholar 

  19. Bar N, Korem T, Weissbrod O, Zeevi D, Rothschild D, Leviatan S, et al. A reference map of potential determinants for the human serum metabolome. Nature. 2020;588:135.

    Article  Google Scholar 

Download references

Acknowledgements

The authors wish to acknowledge all participants of the cohort and the members of the Segal lab for fruitful discussions.

Funding

E.S. is supported by the Crown Human Genome Center; Larson Charitable Foundation New Scientist Fund; Else Kroener Fresenius Foundation; White Rose International Foundation; Ben B. and Joyce E. Eisenberg Foundation; Nissenbaum Family; Marcos Pinheiro de Andrade and Vanessa Buchheim; Lady Michelle Michels; Aliza Moussaieff; and grants funded by the Minerva foundation with funding from the Federal German Ministry for Education and Research and by the European Research Council and the Israel Science Foundation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Eran Segal.

Ethics declarations

Conflict of interest

All author declares that they have no conflict of interest.

Consent to participate

All participants provided written informed consent.

Ethics approval

Ethics approval was granted by the Institutional Review Board (IRB) of the Weizmann Institute of Science.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shilo, S., Bar, N., Keshet, A. et al. 10 K: a large‐scale prospective longitudinal study in Israel. Eur J Epidemiol 36, 1187–1194 (2021). https://doi.org/10.1007/s10654-021-00753-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10654-021-00753-5

Keywords

Navigation